ZYBERNO
Stock Report
Updated Aug 31, 2026

Kazia Therapeutics Limited. (KZIA)

Healthcare • NASDAQ

$13.60

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
7.0/100
POOR BUSINESS
Kazia Therapeutics Limited. (KZIA) scores 7/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (0.0%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.00x)
Operating Margin (Operational Efficiency):CRITICAL (0.0%)
Return on Capital (Capital Efficiency):CRITICAL (0.0%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

Kazia Therapeutics Limited. (KZIA) stock report — Zyberno Score 7/100 (POOR BUSINESS). Full financial analysis on Zyberno.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:13.60
Market Cap:$150.46M

Valuation Multiples (2)

P/S Ratio:5,080.42x
Peg Ratio:-999.00x

Enterprise Metrics (2)

Enterprise Value:$147.68M
Ev Ebitda Ratio:112.05x

Price Action & Momentum (3)

Momentum Percentile:94 / 100
% of 52-Week High:78.2%
B. Profitability Assessment

Margin Analysis (1)

Ebitda Margin:4,450.0%

Yield Metrics (2)

Earnings Yield:-$999.00
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:0.35x
Quick Ratio:0.35x
Cash Ratio:0.31x

Leverage Analysis (1)

Debt To Ebitda:0.21x

Coverage Ratios (2)

Interest Coverage Ratio:0.00x
Times Interest Earned:0.00

Capital Structure (4)

Working Capital:-6,430,326.68
Cash And Cash Equivalents:3,063,907.17
Long Term Debt:$0.00
Net Debt:-$2.78M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

$29.62K
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00$0.00

Bottom Line Performance (3)

-$14.60M
Income Before Tax:$0.00
Ebitda Ttm:1,317,938.43

Operating Expenses (5)

Operating Expenses:0.00
R And D Expense:0.00
Sga Expense:0.00
Income Tax Expense:-$1.23M
Interest Expense:5,121.56

Expense Ratios (3)

R And D To Revenue Percentage:0.0%
Sga To Revenue Percentage:0.0%
Ebitda Margin:4,450.0%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$4.27M
Current Assets:$3.48M
Ppe Net:705.16
Goodwill:0.00
Intangible Assets:$766.51K

Liability Structure (4)

Total Liabilities:10,127,464.83
Current Liabilities:9,909,571.32
Long Term Debt:$0.00
Short Term Debt:$279.24K

Equity & Capital (3)

Equity:-$5.85M
Retained Earnings:$0.00
Common Stock:0.00

Working Capital Items (3)

Accounts Receivable:69,105.39
Inventory:0.00
Accounts Payable:3,980,611.27

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:0.00
C. Cash Flow Analysis

Operating Activities (2)

-$9.36M-$9.37M

Investment Activities (1)

Investing Cash Flow:$0.00

Financing Activities (3)

Financing Cash Flow:$11.27M
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:0.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (1)

Earnings Per Share Ttm:-$1.32

Revenue & Cash Per Share (2)

Sales Per Share Ttm:0.00
Operating Cash Flow Per Share:-$0.85

Book Value & Capital (2)

Book Value Per Share:-$0.53
Cash Per Share:0.28

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.01x
Working Capital Turnover Ttm:-999.00x

Receivables Management (2)

Receivables Turnover Ttm:0.43x
Days Sales Outstanding Ttm:851.67

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:49,057.74
Cash Conversion Cycle:-49,205.07
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:20.00
Quality Score:20.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework
B. Log-Linear Regression Growth Analysis
C. Company Profile & Context

Corporate Information (6)

Symbol:KZIA
Company Name:Kazia Therapeutics Limited.
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:medium
Volume Category:N/A

Share Structure (3)

Shares Outstanding:11.06M
Shares Outstanding Basic:0
Shares Outstanding Diluted:0

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-08-31 14:32:25 UTC
Data Timestamp:2026-08-19T10:07:33.886010
Scroll to Top